Biomed Central Ltd

SHERPA: Unknown

People

  1. Aghajanian
    Aghajanian
  2. Budhu
    Budhu
  3. Iasonos
    Iasonos
  4. Liu
    Liu
  5. Zhou
    Zhou
  6. Balachandran
    Balachandran
  7. Ceglia
    Ceglia
  8. Chan
    Chan
  9. De Stanchina
    De Stanchina
  10. Grisham
    Grisham

Groups

  1. Department of Medicine (20)
  2. GDMT, Medicine (20)
  3. Gynecologic Medicine Service (20)
  4. Gynecology Disease Management Team (20)
  5. Solid Tumor Oncology Division (20)
  6. Melanoma and Immunotherapeutics Service (10)
  7. GSK Faculty (9)
  8. Hematology-Oncology Fellows (4)
  9. Biostatistics Service (3)
  10. Epidemiology and Biostatistics (3)
Search Within
  1. "Dmitriy Zamarin"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (5)
  3. Guidelines (1)
Groups
  1. Department of Medicine (20)
  2. GDMT, Medicine (20)
  3. Gynecologic Medicine Service (20)
  4. Gynecology Disease Management Team (20)
  5. Solid Tumor Oncology Division (20)
  6. Melanoma and Immunotherapeutics Service (10)

More Groups

People
  1. Dmitriy Zamarin (20)
  2. Taha Merghoub (9)
  3. Jedd Wolchok (8)
  4. Rikke Holmgaard (4)
  5. Claire Friedman (3)
  6. Alexia Iasonos (2)

More People

Years
  1. 2024 (1)
  2. 2022 (2)
  3. 2021 (1)
  4. 2020 (7)
  5. 2019 (1)
  6. 2018 (1)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (20)

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
    Journal Article

    Davar, D.; Carneiro, B. A.; Dy, G. K.; Sheth, S.; Borad, M. J.; Harrington, K. J.; Patel, S. P.; Galanis, E.; Samson, A.; Agrawal, S.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • MEDI1191 (IL-12 MRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (c/sc) lesions
    Meeting Abstract

    Abadier, M.; Jennings, E.; Eyles, J.; Martin, P.; Pilataxi, F.; Wu, Y.; Chen, X.; Azaro, A.; Ridgway, B.; Phillips, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naìˆve or experienced for immune checkpoint blockade
    Journal Article

    Gomez-Roca, C.; Cassier, P.; Zamarin, D.; Machiels, J. P.; Perez Gracia, J. L.; Hodi, F. S.; Taus, A.; Martinez Garcia, M.; Boni, V.; Eder, J. P.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade
    Meeting Abstract

    Muroyama, Y.; Manne, S.; Greenplate, A.; Mathew, D.; Oldridge, D.; Chilukuri, L.; Xu, C.; Herati, R.; Huang, A.; Zamarin, D.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Tim-4(+) resident macrophages impair anti-tumor immunity in the serous body cavities by sequestering viable and cytotoxic CD8(+) T cells expressing high levels of phosphatidylserine
    Meeting Abstract

    Chow, A.; Schad, S.; Green, M.; Hellmann, M.; Ceglia, N.; Allaj, V.; Zago, G.; Shah, N.; Sharma, S.; Mattar, M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells
    Meeting Abstract

    Draganov, D.; Santidrian, A.; Minev, I.; Nguyen, D.; Zamarin, D.; Marincola, F.; Minev, B.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Distinct immune signatures predicting clinical response to PD-1 blockade therapy in gynecological cancers revealed by high-dimensional immune profiling
    Meeting Abstract

    Muroyama, Y.; Muroyama, Y.; Manne, S.; Huang, A.; Mathew, D.; Chilukuri, L.; Greenplate, A.; Ohtani, T.; Zamarin, D.; Friedman, C.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
    Journal Article

    Machiels, J. P.; Gomez-Roca, C.; Michot, J. M.; Zamarin, D.; Mitchell, T.; Catala, G.; Eberst, L.; Jacob, W.; Jegg, A. M.; Cannarile, M. A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
    Journal Article

    Friedman, C. F.; Snyder Charen, A.; Zhou, Q.; Carducci, M. A.; Buckley De Meritens, A.; Corr, B. R.; Fu, S.; Hollmann, T. J.; Iasonos, A.; Konner, J. A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: A phase II trial
    Journal Article

    Zamarin, D.; Walderich, S.; Holland, A.; Zhou, Q.; Iasonos, A. E.; Torrisi, J. M.; Merghoub, T.; Chesebrough, L. F.; Mcdonnell, A. S.; Gallagher, J. M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save